Search

Your search keyword '"Tighe, Jane"' showing total 10 results
Start Over Author "Tighe, Jane" Journal british journal of haematology
10 results on '"Tighe, Jane"'

1. Optimizing the management of patients with spinal myeloma disease

Author

Molloy, Sean, Lai, Maggie, Pratt, Guy, Ramasamy, Karthik, Wilson, David, Quraishi, Nasir, Auger, Martin, Cumming, David, Punekar, Maqsood, Quinn, Michael, Ademonkun, Debo, Willis, Fenella, Tighe, Jane, Cook, Gordon, Stirling, Alistair, Bishop, Timothy, Williams, Cathy, Boszczyk, Bronek, Reynolds, Jeremy, Grainger, Mel, Craig, Niall, Hamilton, Alastair, Chalmers, Isobel, Ahmedzai, Sam, Selvadurai, Susanne, Low, Eric, and Kyriakou, Charalampia

Published
2015
Full Text
View/download PDF

3. Re-transplantation after bortezomib-based therapy

Author

Morris, Curly, Cook, Gordon, Streetly, Matthew, Kettle, Paul, Drake, Mary, Quinn, Michael, Cavet, Jim, Tighe, Jane, Kazmi, Majit, Ashcroft, John, Cook, Mark, Snowden, John, Olujohungbe, Ade, Marshall, Scott, Conn, Jane, Oakervee, Heather, Popat, Rakesh, and Cavenagh, Jamie

Published
2011
Full Text
View/download PDF

4. Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study

Author

Milojkovic, Dragana, primary, Cross, Nicholas C. P., additional, Ali, Sahra, additional, Byrne, Jenny, additional, Campbell, Gavin, additional, Dignan, Fiona L., additional, Drummond, Mark, additional, Huntly, Brian, additional, Marshall, Scott, additional, McMullin, Mary Frances, additional, Neelakantan, Pratap, additional, Raghavan, Manoj, additional, Sivakumaran, Muttuswamy, additional, Tighe, Jane, additional, Wandroo, Farooq, additional, Willis, Fenella, additional, Glen, Fiona, additional, Fildes, Louise, additional, Collington, Sarah J., additional, Ryan, Jacqueline, additional, Clark, Richard E., additional, and Mead, Adam J., additional

Published
2020
Full Text
View/download PDF

7. Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.

Author

Milojkovic, Dragana, Cross, Nicholas C. P., Ali, Sahra, Byrne, Jenny, Campbell, Gavin, Dignan, Fiona L., Drummond, Mark, Huntly, Brian, Marshall, Scott, McMullin, Mary Frances, Neelakantan, Pratap, Raghavan, Manoj, Sivakumaran, Muttuswamy, Tighe, Jane, Wandroo, Farooq, Willis, Fenella, Glen, Fiona, Fildes, Louise, Collington, Sarah J., and Ryan, Jacqueline

Subjects
PROTEIN-tyrosine kinase inhibitors, CHRONIC myeloid leukemia, CARDIOVASCULAR diseases risk factors, NILOTINIB, PATIENT care
Abstract

Summary: Management of chronic myeloid leukaemia (CML) has recently undergone dramatic changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; however, it remains unclear whether real‐world CML management is consistent with these goals. We report results of UK TARGET CML, a retrospective observational study of 257 patients with chronic‐phase CML who had been prescribed a first‐line TKI between 2013 and 2017, most of whom received first‐line imatinib (n = 203). Although 44% of patients required ≥1 change of TKI, these real‐world data revealed that molecular assessments were frequently missed, 23% of patients with ELN‐defined treatment failure did not switch TKI, and kinase domain mutation analysis was performed in only 49% of patients who switched TKI for resistance. Major molecular response (MMR; BCR‐ABL1IS ≤0·1%) and deep molecular response (DMR; BCR‐ABL1IS ≤0·01%) were observed in 50% and 29%, respectively, of patients treated with first‐line imatinib, and 63% and 54%, respectively, receiving a second‐generation TKI first line. MMR and DMR were also observed in 77% and 44% of evaluable patients with ≥13 months follow‐up, receiving a second‐generation TKI second line. We found little evidence that cardiovascular risk factors were considered during TKI management. These findings highlight key areas for improvement in providing optimal care to patients with CML. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

8. Safety and efficacy of pulsed imatinib with or without G-CSFversuscontinuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up

Author

Gallipoli, Paolo, primary, Stobo, Jon, additional, Heaney, Nicholas, additional, Nicolini, Franck E., additional, Clark, Richard, additional, Wilson, George, additional, Tighe, Jane, additional, McLintock, Lorna, additional, Hughes, Timothy, additional, Michor, Franziska, additional, Paul, James, additional, Drummond, Mark, additional, and Holyoake, Tessa L., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results